CompletedNCT01315457Updated May 24, 2012

Infections Associated With the Use of Alemtuzumab

An observational study in Patients Treated With Alemtuzumab, sponsored by Samsung Medical Center. Completed at 5 sites in 5 countries. Open to participants aged 15 Years to 90 Years. Per ClinicalTrials.gov, last updated 2012-05-24.

Sponsored by Samsung Medical Center · Observational

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 182
Ages: 15 Years to 90 Years
Sex: All

Study summary

The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab

Conditions studied

Patients Treated With Alemtuzumab

Keywords

alemtuzumab, infection, prophylaxis, treatment

In context

Lead sponsor

Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 15 Years to 90 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

Patients received alemtuzumab as a treatment for hematologic malignancy

Inclusion criteria

Patients received alemtuzumab as a treatment for hematologic malignancy ex. non-Hodgkin lymphoma Acute myeloid leukemia Aplastic anemia

Exclusion criteria

Exclusion Criteria:

Patients did not receive alemtuzumab

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 182 participants (actual)

Groups and cohorts

Alemtuzumab
Patients treated with alemtuzumab

What researchers measure

Primary outcomes

Infectious event
Any infectious complication occurred within one year after the use of alemtuzumab
Time frame: one year

Study locations

5 sites

Queen Mary Hospital
Hong Kong, China
Cipto Mangunkusumo General Hospital
Jakarta, Indonesia
Samsung Medical Center
Seoul, Korea, Republic of
National Taiwan University Hospital
Teipei, Taiwan
Chulalongkorn University
Bangkok, Thailand

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on May 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01315457
Lead sponsor: Samsung Medical Center
Collaborators: National Taiwan University Hospital, Dr Cipto Mangunkusumo General Hospital, Asan Medical Center, Soon Chun Hyang University, Chonnam National University, Chonbuk National University, Chulalongkorn University, Queen Mary Hospital, Hong Kong, Yonsei University, Kyungpook National University Hospital
Responsible party: Won Seog Kim (Professor, Samsung Medical Center) — Principal investigator
First posted: Mar 15, 2011
Start date: Apr 2009
Primary completion: Mar 2012
Completion: Mar 2012
Last update: May 24, 2012

Study contacts

Won Seog Kim, MD, PhD

principal investigator · Samsung Medical Center

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Samsung Medical Center

Start the discussion